MARD

Type 2 diabetes is not one-size-fits-all: Subtypes affect complications and treatment options

Retrieved on: 
Friday, April 19, 2024

You may have heard of Ozempic, the “miracle drug” for weight loss, but did you know that it was actually designed as a new treatment to manage diabetes?

Key Points: 
  • You may have heard of Ozempic, the “miracle drug” for weight loss, but did you know that it was actually designed as a new treatment to manage diabetes?
  • In Canada, diabetes affects approximately 10 per cent of the general population.

Locks and keys

  • Every cell in the body needs sugar as an energy source, but too much sugar can be toxic to cells.
  • This equilibrium needs to be tightly controlled and is regulated by a lock and key system.
  • Cells cover themselves with locks that respond perfectly to insulin keys to facilitate the entry of sugar into cells.
  • The body can encounter difficulties producing an adequate number of insulin keys, and/or the locks can become stubborn and unresponsive to insulin.

Severe insulin-deficient diabetes: We’re missing keys!

  • In the severe insulin-deficient diabetes (SIDD) subtype, the key factories — the beta cells — are on strike.
  • Why the beta cells go on strike remains largely unknown, but since there is an insulin deficiency, treatment often involves insulin injections.

Severe insulin-resistant diabetes: But it’s always locked!

  • In the severe insulin-resistant diabetes (SIRD) subtype, the locks are overstimulated and start ignoring the keys.
  • There are many treatment avenues for these patients but no consensus about the optimal approach; patients often require high doses of insulin.

Mild obesity-related diabetes: The locks are sticky!

  • Mild obesity-related (MOD) diabetes represents a nuanced aspect of Type 2 diabetes, often observed in individuals with higher body weight.
  • The locks are “sticky,” so it is challenging for the key to click in place and open the lock.

Mild age-related diabetes: I’m tired of controlling blood sugar!


Mild age-related diabetes (MARD) happens more often in older people and typically starts later in life. With time, the key factory is not as productive, and the locks become stubborn. People with MARD find it tricky to manage their blood sugar, but it usually doesn’t lead to severe complications. Among the different subtypes of diabetes, MARD is the most common.

Unique locks, varied keys

  • In Canada, unique cases of Type 2 diabetes were identified in Indigenous children from Northern Manitoba and Northwestern Ontario by Dr. Heather Dean and colleagues in the 1980s and 90s.
  • Read more:
    Indigenous community research partnerships can help address health inequities

    Childhood-onset Type 2 diabetes is on the rise across Canada, but disproportionately affects Indigenous youth.

  • Acknowledging this distinct subtype of Type 2 diabetes in First Nations communities has led to the implementation of a community-based health action plan aimed at addressing the unique challenges faced by Indigenous Peoples.

A mosaic of conditions

  • Type 2 diabetes is not uniform; it’s a mosaic of conditions, each with its own characteristics.
  • Since diabetes presents so uniquely in every patient, even categorizing into subtypes does not guarantee how the disease will evolve.


Lili Grieco-St-Pierre receives funding from Fonds de recherche du Québec - Santé (FRQS). Jennifer Bruin receives funding from the Canadian Institutes of Health Research (CIHR), Natural Sciences and Engineering Research Council of Canada (NSERC), JDRF, Diabetes Canada.

Know Labs to Present Clinical Research at the 2024 American Physiology Summit

Retrieved on: 
Friday, April 5, 2024

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit in Long Beach, California on April 4-7, 2024.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit in Long Beach, California on April 4-7, 2024.
  • At the previous APS Summit, Know Labs presented results from its peer-reviewed, proof-of-principle study conducted in collaboration with Mayo Clinic, which assessed the accuracy of its RF dielectric sensor in identifying different analytes in vitro, proving a 100% accuracy rate in these tests.
  • Since then, Know Labs has published several clinical studies demonstrating the stability, repeatability, and accuracy of its non-invasive continuous blood glucose monitor.
  • Most recently, Know Labs announced interim results from its first clinical research protocol involving people with diabetes, using venous blood as a comparative reference and a machine learning model trained on data collected in a lab setting, which resulted in an overall MARD of 11.1%.

Know Labs’ Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study

Retrieved on: 
Wednesday, March 6, 2024

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced interim results from its most recent clinical research study.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced interim results from its most recent clinical research study.
  • Dr. Virend K. Somers of the Mayo Clinic serves as an author and co-investigator on the clinical research protocol.
  • “Despite significant efforts in the development of non-invasive blood glucose monitoring solutions, delivering a highly accurate, economical, FDA-cleared non-invasive continuous glucose monitor (CGM) still remains to be seen.
  • On the held-out test dataset, blood glucose was estimated with a MARD of 11.1 ± 2.1% relative to venous blood.

Spiden Announces Breakthrough in Non-Invasive Glucose Monitoring, Adds Key Executive Hires and Secures $15m in Additional Funding

Retrieved on: 
Saturday, January 6, 2024

Spiden's latest non-invasive glucose measurement campaignSpiden's latest glucose measurement data comparing its non-invasive portable device (y-axis) with the invasive gold-standard (x-axis), illustrated in the Clarke Error Grid.

Key Points: 
  • Spiden's latest non-invasive glucose measurement campaignSpiden's latest glucose measurement data comparing its non-invasive portable device (y-axis) with the invasive gold-standard (x-axis), illustrated in the Clarke Error Grid.
  • Spiden has achieved remarkable scientific progress in non-invasive glucose sensing.
  • This achievement is the latest important step towards a calibration-free and miniaturized device for non-invasive glucose monitoring.
  • A larger funding round is planned for H2 in 2024, which will provide Spiden with sufficient capital to bring its product to market and become profitable.

GLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

Retrieved on: 
Tuesday, January 2, 2024

The Company announces the successful completion of their first preclinical study of the implantable CBGM.

Key Points: 
  • The Company announces the successful completion of their first preclinical study of the implantable CBGM.
  • In comparison, many continuous glucose monitoring (CGM) systems measure glucose in the interstitial fluid, which lags behind blood glucose.
  • The Company also announces a second milestone: the commencement of long-term preclinical testing on the implantable CBGM.
  • GlucoTrack is committed to commercializing an implantable CBGM with a long-term sensor life, no requirement for an additional wearable component, and a once-only calibration event.

SIBIONICS Achieves Milestone: Receiving CE Mark for Its Groundbreaking GS1 Continuous Glucose Monitoring System

Retrieved on: 
Wednesday, November 1, 2023

SHENZHEN, China, Nov. 1, 2023 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring System (CGM) brand, is delighted to announce that it has received the CE Mark for its revolutionary GS1 CGM.

Key Points: 
  • SHENZHEN, China, Nov. 1, 2023 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring System (CGM) brand, is delighted to announce that it has received the CE Mark for its revolutionary GS1 CGM.
  • Founded in 2015, SIBIONICS boasts a workforce exceeding 700 individuals, with over 40% actively engaged in research and development efforts.
  • The SIBIONICS GS1 CGM offers users 14 days of calibration-free continuous glucose monitoring solution, empowering them with the capability to transmit glucose data to their monitoring devices or mobile applications and generate professional AGP reports.
  • Starting today, SIBIONICS GS1 CGM products will gradually become available for pre-sales in EU countries, the UK, and other European countries.

SIBIONICS Achieves Milestone: Receiving CE Mark for Its Groundbreaking GS1 Continuous Glucose Monitoring System

Retrieved on: 
Wednesday, November 1, 2023

SHENZHEN, China, Nov. 1, 2023 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring System (CGM) brand, is delighted to announce that it has received the CE Mark for its revolutionary GS1 CGM.

Key Points: 
  • SHENZHEN, China, Nov. 1, 2023 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring System (CGM) brand, is delighted to announce that it has received the CE Mark for its revolutionary GS1 CGM.
  • Founded in 2015, SIBIONICS boasts a workforce exceeding 700 individuals, with over 40% actively engaged in research and development efforts.
  • The SIBIONICS GS1 CGM offers users 14 days of calibration-free continuous glucose monitoring solution, empowering them with the capability to transmit glucose data to their monitoring devices or mobile applications and generate professional AGP reports.
  • Starting today, SIBIONICS GS1 CGM products will gradually become available for pre-sales in EU countries, the UK, and other European countries.

Nemaura Medical Completes 100 Patient Study for sugarBEAT® 24-hour Wear and Reports Interim Results

Retrieved on: 
Monday, September 11, 2023

The Company has previously received CE approval in Europe, and SFDA (Saudi Food and Drug Authority) approval for its sugarBEAT® glucose sensor for a wear period of 14 hours.

Key Points: 
  • The Company has previously received CE approval in Europe, and SFDA (Saudi Food and Drug Authority) approval for its sugarBEAT® glucose sensor for a wear period of 14 hours.
  • This study was designed to evaluate several factors, including the possibility of increasing the wear period to up to 24 hours, evaluating the possibility of auto-calibration, and different methods of application of the device to the skin.
  • The Company reports interim data from a first cohort comprising 25 patients, on a single day sensor wear.
  • The results indicate that a 24-hour sensor wear period using a single sensor is possible, which is expected to allow users to monitor their glucose fluctuations overnight.

Leaders Gather for The 3rd Global Food Security & Sustainability Summit

Retrieved on: 
Thursday, August 31, 2023

DA NANG, VIETNAM, Aug 31, 2023 - (ACN Newswire) - Fifteen leaders gathered for The 3rd Global Food Security & Sustainability Summit in Danang, Vietnam on August 29, 2023.

Key Points: 
  • DA NANG, VIETNAM, Aug 31, 2023 - (ACN Newswire) - Fifteen leaders gathered for The 3rd Global Food Security & Sustainability Summit in Danang, Vietnam on August 29, 2023.
  • The summit focused on scaling up climate resilience and transforming food value chains to mitigate ESG risks, attracting key stakeholders, policymakers, government institutions, investors and United Nations bodies.
  • Mr. Remi Nono Womdim, Representative of the Food and Agriculture Organization of the United Nations (FAO) in Viet Nam, presented a global perspective in "Averting A Global Food Crisis - What Must Be Done?"
  • The summit brought new perspectives and opened conversations to effectively tackle the imminent challenges addressed in food security and sustainability.

Apollon and MIT Commence Collaboration to Develop Continuous Non-Invasive Glucose Monitoring Technology

Retrieved on: 
Monday, August 21, 2023

Dr. Peter So, Professor of Mechanical and Biological Engineering and Director of the MIT LBRC, and Dr. Jeonwoong Kang of the Department of Mechanical Engineering will lead the collaboration.

Key Points: 
  • Dr. Peter So, Professor of Mechanical and Biological Engineering and Director of the MIT LBRC, and Dr. Jeonwoong Kang of the Department of Mechanical Engineering will lead the collaboration.
  • As a result of Apollon's expertise in Raman diagnostics and spectrometer miniaturization, MIT will invite Dr. Youngkyu Kim of Apollon as a visiting scientist.
  • Dr. Kang published a paper in the prestigious journal Science Advances in 2020 that directly measured glucose concentration without drawing blood by irradiating the skin with laser light.
  • It was funded by the National Institutes of Health and Samsung Advanced Institute of Technology.